Financial Performance - Net profit attributable to shareholders rose by 32.61% to CNY 45,011,163.00 year-on-year[5] - Operating revenue grew by 16.48% to CNY 804,063,401.00 compared to the same period last year[5] - Basic earnings per share increased by 32.61% to CNY 0.1076[5] - The weighted average return on equity improved by 0.40 percentage points to 2.19%[5] - Total operating revenue for Q1 2019 was CNY 804,063,401, an increase of 16.5% compared to CNY 690,326,657 in Q1 2018[39] - Net profit for Q1 2019 reached CNY 55,348,091.30, representing a 30.4% increase from CNY 42,422,124.99 in Q1 2018[40] - Earnings per share for Q1 2019 was CNY 0.1076, compared to CNY 0.0811 in Q1 2018, indicating a growth of 32.3%[40] - The total profit for Q1 2019 was CNY 26,155,937.40, an increase of 18.5% from CNY 22,129,712.25 in Q1 2018[42] Cash Flow - Net cash flow from operating activities surged by 133.28% to CNY 48,074,675.33 compared to the previous year[5] - The net cash flow from operating activities increased by CNY 27,466,903.75, representing a growth of 133.28% compared to the previous year, primarily due to the increase in net profit and a greater rise in operating payables than receivables[26] - The net cash flow from investing activities improved by CNY 219,541,210.79 compared to the previous year, mainly due to no investment payments in financial products and redemptions from money market funds during the period[27] - The net cash flow from financing activities decreased by CNY 2,536,005.48, primarily due to an increase in loan repayments compared to the previous period[27] - Cash flow from operating activities generated a net amount of CNY 48,074,675.33, compared to CNY 20,607,771.58 in Q1 2018[47] - The net cash flow from investment activities was CNY 86,551,712.02, a turnaround from a negative CNY 135,815,682.63 in Q1 2018[50] Assets and Liabilities - Total assets increased by 6.21% to CNY 3,688,229,489.77 compared to the end of the previous year[5] - The total liabilities as of March 31, 2019, were CNY 1,180,652,382.91, up from CNY 1,042,523,613.03 at the end of the previous year[32] - The total equity attributable to shareholders reached CNY 2,096,152,141.94, compared to CNY 2,028,833,840.59 at the end of the previous year[32] - Cash and cash equivalents increased to CNY 1,119,667,056.25 from CNY 991,126,636.45 at the end of the previous year[30] - Accounts receivable rose to CNY 871,958,752.72 from CNY 845,909,702.75 at the end of the previous year, with accounts receivable specifically increasing to CNY 367,708,385.46 from CNY 191,981,469.66[30] - Inventory increased to CNY 486,866,720.62 from CNY 440,852,066.28 at the end of the previous year[30] - The company reported a total current liabilities of CNY 1,094,195,263.81, an increase from CNY 955,927,049.89 at the end of the previous year[32] Shareholder Information - The total number of shareholders reached 32,394 at the end of the reporting period[10] - The largest shareholder, Zhuzhou State-owned Assets Investment Holding Group, holds 28.53% of the shares[10] Research and Development - Research and development expenses grew by 42.18% year-on-year, mainly due to increased capitalized R&D expenditures[21] - Research and development expenses for Q1 2019 amounted to CNY 19,168,032.20, an increase of 42.3% from CNY 13,481,465.45 in Q1 2018[39] - Research and development expenses increased to CNY 8,347,231.84, up from CNY 7,832,351.11 in the same period last year[42] Financial Instruments and Standards - Trading financial assets increased by 100% compared to the previous period, reflecting the company's first-time implementation of new financial instrument standards[12] - The company reported a 100% decrease in available-for-sale financial assets, as these were reclassified under new financial instrument standards[15] - The company adopted new financial instrument standards starting January 1, 2019, affecting the classification of financial assets[54] - The reclassification of available-for-sale financial assets to "financial assets measured at fair value and changes recognized in profit or loss" was noted[59]

Financial Performance - Operating income rose by 16.48% to CNY 804,063,401.00 year-on-year[6] - Net profit attributable to shareholders increased by 43.18% to CNY 40,637,650.72 compared to the same period last year[6] - Basic earnings per share increased by 28.48% to CNY 0.1042[6] - The weighted average return on equity improved by 0.34 percentage points to 2.13%[6] - Total operating revenue for Q1 2019 reached ¥804,063,401, an increase of 16.5% compared to ¥690,326,657 in Q1 2018[37] - Net profit for Q1 2019 was ¥53,944,808, representing a 27.3% increase from ¥42,422,125 in Q1 2018[38] - Earnings per share for Q1 2019 were ¥0.1042, compared to ¥0.0811 in Q1 2018, reflecting a growth of 28.8%[38] - Operating profit for Q1 2019 was CNY 25,068,346.95, an increase of 13.7% from CNY 22,054,589.45 in Q1 2018[40] Cash Flow - Cash flow from operating activities surged by 133.28% to CNY 48,074,675.33 year-on-year[6] - The company's cash flow from operating activities increased by 133.28%, reaching ¥48,074,675.33 compared to ¥20,607,771.58 in the previous period[24] - Operating cash inflow for Q1 2019 was CNY 335,297,155.54, an increase of 35.2% compared to CNY 248,038,516.73 in Q1 2018[45] - Net cash flow from operating activities decreased to CNY 5,213,209.94 from CNY 54,078,606.91 year-over-year, representing a decline of 90.3%[46] - Cash inflow from investment activities totaled CNY 301,583,985.26, compared to CNY 125,182,738.21 in Q1 2018, indicating a growth of 141.5%[44] - Investment cash inflow for Q1 2019 was CNY 299,543,146.90, significantly higher than CNY 122,567,330.75 in Q1 2018, marking an increase of 144.4%[46] - Net cash flow from investing activities improved to CNY 86,551,712.02 from a negative CNY 135,815,682.63 year-over-year[46] Assets and Liabilities - Total assets increased by 6.12% to CNY 3,685,166,836.74 compared to the end of the previous year[6] - The company's current assets reached CNY 2,789,132,694.78, up from CNY 2,596,320,070.99 at the end of 2018, indicating an increase of about 7.4%[28] - Total liabilities increased to CNY 1,180,629,796.13 from CNY 1,042,523,613.03, representing a rise of about 13.2%[30] - The company's equity attributable to shareholders rose to CNY 2,093,112,075.69 from CNY 2,028,833,840.59, indicating an increase of approximately 3.2%[30] - The total liabilities as of Q1 2019 amounted to ¥361,021,766, a slight decrease from ¥369,283,728 in the previous year[34] - Total liabilities amounted to CNY 1,042,523,613.03, with current liabilities at CNY 955,927,049.89 and non-current liabilities at CNY 86,596,563.14[49] Shareholder Information - The total number of shareholders reached 32,394 at the end of the reporting period[12] - The largest shareholder, Zhuzhou State-owned Assets Investment Holding Group, holds 28.53% of the shares[12] Research and Development - Research and development expenses grew by 42.18%, amounting to ¥19,168,032.20 compared to ¥13,481,465.45 in the same period last year[21] - Research and development expenses increased to ¥19,168,032, up 42.3% from ¥13,481,465 in Q1 2018[37] - Research and development expenses increased to CNY 8,347,231.84, representing a rise of 6.6% from CNY 7,832,351.11 in Q1 2018[40] Other Financial Metrics - Government subsidies recognized in the current period amounted to CNY 2,630,214.55[9] - Non-recurring gains and losses totaled CNY 2,970,228.88 for the reporting period[9] - The company reported a significant increase in other receivables, which rose to CNY 142,462,201.13 from CNY 61,673,500.09, representing a growth of approximately 130%[28] - The company reported a financial cost of -¥6,157,881 in Q1 2019, which is an increase in income compared to -¥3,356,346 in Q1 2018[37] - The company recorded a financial expense of CNY -7,398,930.81, compared to CNY -4,562,303.57 in Q1 2018, indicating a worsening in financial costs[40] Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[39]

Financial Performance - In 2018, the net profit attributable to shareholders of the listed company was CNY 255,355,306.05, representing a year-on-year increase of 22.91%[5]. - The operating revenue for 2018 was CNY 3,328,553,963.17, an increase of 4.58% compared to the previous year[20]. - The net cash flow from operating activities reached CNY 383,466,469.60, marking a 33.42% increase from 2017[20]. - The total assets at the end of 2018 amounted to CNY 3,472,489,217.17, reflecting a growth of 5.65% year-on-year[20]. - The net assets attributable to shareholders of the listed company were CNY 2,028,833,840.59, an increase of 8.07% compared to the end of 2017[20]. - Basic earnings per share (EPS) increased by 22.93% to CNY 0.6102 in 2018 compared to CNY 0.4964 in 2017[21]. - The weighted average return on equity rose to 13.07%, an increase of 1.60 percentage points from 11.47% in 2017[21]. - The net profit attributable to shareholders for Q4 2018 was CNY 116,893,942.90, with a total annual revenue of CNY 3,328,554,963.17[26]. - Non-recurring gains for 2018 amounted to CNY 44,199,798.58, compared to CNY 34,657,943.01 in 2017[26]. - The company achieved a profit of 352 million yuan in 2018, representing a year-on-year increase of 22.91%[43]. - The company's operating revenue reached 3.329 billion yuan, with a year-on-year growth of 4.58%[43]. Dividend Policy - The company plans to distribute a cash dividend of CNY 4 per 10 shares based on a total share capital of 418,507,117 shares as of December 31, 2018[5]. - The company distributed cash dividends of approximately RMB 167.40 million in 2018, representing a payout ratio of 65.56% of net profit attributable to ordinary shareholders[139]. - In 2017, the cash dividends amounted to approximately RMB 104.63 million, with a payout ratio of 50.36%[139]. - The company is committed to a cash dividend policy, distributing no less than 20% of the annual distributable profit as cash dividends[137]. Risk Management - The company has identified risks related to raw material price fluctuations, drug quality, industry policies, and R&D in its report[7]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[7]. - The company’s future plans include addressing potential risks as detailed in the operational discussion and analysis section of the report[7]. - The company faces risks from fluctuations in the prices of traditional Chinese medicinal materials, which can significantly impact procurement and cost control[129]. - Quality risks in pharmaceuticals include management and inherent risks, affecting the entire process from raw material procurement to patient use[130]. Research and Development - The research institute is currently working on over 100 projects, with more than 60 related to pharmaceuticals[41]. - The company has a total of 51 products, including 12 exclusive drugs, 4 health foods, and 25 gynecological products[100]. - The total R&D investment for the reporting period was CNY 11,821.12 million, accounting for 3.55% of operating revenue and 4.86% of net assets[105]. - The R&D investment for the gynecological Qianjin capsule was CNY 1,395.14 million, representing 0.42% of operating revenue[103]. - The R&D investment for the blood-enriching Yimother pill increased by 140.85% year-on-year, totaling CNY 471.97 million[103]. - The company has completed 3 registration applications and passed 4 clinical and bioequivalence tests since 2018[101]. - The company is focusing on the development of new drugs and the secondary development of existing products, with a total of 13 ongoing projects in traditional Chinese medicine[101]. Market Position and Strategy - The company has established a full industry chain business structure, including pharmaceutical manufacturing, distribution, and traditional Chinese medicine planting[32]. - The company aims to expand into women's health products and traditional Chinese medicine derivatives beyond its core gynecological focus[32]. - The brand value of "Qianjin" reached 1.869 billion yuan, maintaining its position as the top brand in gynecological medication for four consecutive years[37]. - The marketing strategy includes a "county strategy" that ensures product coverage at the county and grassroots levels, with a 95% distribution rate for gynecological products[39]. - The company has established partnerships with over 1,500 commercial entities and more than 40,000 pharmacies, enhancing its retail network[39]. - The company has successfully entered provincial medical insurance directories with products such as Chuanru Ning Gel and Gancao Zinc Capsules[96]. Corporate Governance - The company’s financial report received a standard unqualified audit opinion from Tianzhi International Accounting Firm[5]. - The company has engaged Tianzhi International Accounting Firm for auditing services, with a fee of RMB 600,000[146]. - The company has not proposed any cash profit distribution plan despite having positive distributable profits for ordinary shareholders[139]. - The company has not disclosed any significant related party transactions or changes in related party transactions during the reporting period[152]. - The company has not reported any shareholding changes that would affect the voting rights of shareholders[200]. Social Responsibility - The company reported a total investment of approximately 71 million yuan in poverty alleviation projects for the year 2018[167]. - The company plans to purchase agricultural products from supported farmers amounting to no less than 6,000 yuan annually from 2019 to 2020[170]. - The company has committed over 20 million yuan to social responsibility initiatives since 2011, including support for education and poverty alleviation[173]. - The company aims to help the targeted impoverished village achieve national poverty alleviation verification by 2020[168]. - The company has outlined a detailed poverty alleviation plan that includes training and employment assistance for impoverished families[170]. Environmental Compliance - The wastewater treatment facilities at the company's plants have a total designed capacity of 2,500 tons per day, with operational compliance reported[179]. - The company has installed online monitoring systems for wastewater at its plants, ensuring real-time data transmission to government platforms[183].

Financial Performance - Net profit attributable to shareholders rose by 41.89% to CNY 138,461,363.15 for the first nine months of the year[6] - Basic and diluted earnings per share increased by 41.85% to CNY 0.33[7] - The weighted average return on equity increased by 1.64 percentage points to 7.11%[7] - Net profit attributable to the parent company's shareholders increased by 41.89% year-on-year, driven by improved resource allocation and profitability across various segments[17] - The net profit attributable to the parent company for the first nine months of 2018 was ¥138,461,363.15, up from ¥97,583,646.98, marking a growth of around 41.8%[31] - The net profit for the third quarter of 2018 was ¥84,196,792.13, compared to ¥63,068,858.30 in the same quarter last year, reflecting an increase of approximately 33.5%[30] - The total profit for the first nine months of 2018 was CNY 110,096,821.28, a significant increase of 23.63% compared to CNY 89,069,523.39 in the same period last year[35] Revenue and Costs - Revenue for the first nine months was CNY 2,290,642,594.53, a slight increase of 0.45% year-on-year[6] - Total operating revenue for the first nine months of 2018 reached ¥2,290,642,594.53, a slight increase from ¥2,280,331,808.96 in the same period last year, representing a growth of approximately 0.6%[28] - Total operating costs for the first nine months of 2018 were ¥2,127,313,035.15, down from ¥2,157,156,359.32, indicating a decrease of about 1.4%[28] - The company’s total operating costs for Q3 2018 were CNY 58,751,558.10, which is an increase of 4.26% compared to CNY 55,387,596.14 in Q3 2017[34] Cash Flow - Operating cash flow increased by 67.80% to CNY 298,261,662.22 year-to-date[6] - Operating cash inflow for the year-to-date period reached ¥855.38 million, a 31.4% increase from ¥650.25 million in the same period last year[40] - Net cash flow from operating activities was ¥258.84 million, up 62.0% compared to ¥159.88 million in the previous year[40] - The cash flow from operating activities for the first nine months of 2018 was CNY 298,261,662.22, compared to CNY 177,753,186.38 in the previous year, indicating a growth of 67.73%[38] - The company reported a net cash outflow from investing activities of CNY -389,282,608.17 for the first nine months of 2018, slightly improved from CNY -424,327,636.02 in the same period last year[38] - Cash inflow from investment activities totaled ¥482.24 million, significantly higher than ¥150.90 million in the same period last year[40] - Net cash flow from investment activities was -¥324.06 million, an improvement from -¥346.27 million year-over-year[40] Assets and Liabilities - Total assets increased by 2.42% to CNY 3,366,552,725.31 compared to the end of the previous year[6] - Total current assets increased to CNY 2,515,824,940.33 from CNY 2,429,237,726.97, representing a growth of approximately 3.6%[22] - Total liabilities rose to CNY 1,074,859,600.84 from CNY 1,045,713,417.43, an increase of approximately 2.8%[23] - Total equity attributable to shareholders increased to CNY 1,915,083,716.00 from CNY 1,877,407,342.85, reflecting a growth of about 2.0%[24] - Non-current liabilities decreased to CNY 95,181,914.80 from CNY 111,328,036.15, a decline of about 14.5%[23] Shareholder Information - The total number of shareholders at the end of the reporting period was 28,811[10] - The largest shareholder, Zhuzhou State-owned Assets Investment Holding Group Co., Ltd., holds 28.53% of the shares[11] Government Support - The company received government subsidies totaling CNY 7,031,520.35 year-to-date, closely related to its normal business operations[8] Other Financial Metrics - Cash and cash equivalents decreased by 52.01% compared to the beginning of the year, primarily due to an increase in investment funds[13] - Financial assets measured at fair value and recognized in profit or loss increased by 97.13% compared to the beginning of the year, mainly due to an increase in money market funds[13] - Other receivables increased by 83.92% compared to the beginning of the year, primarily due to an increase in the company's petty cash[13] - Construction in progress increased by 83.23% compared to the beginning of the year, mainly due to an increase in the parent company's construction projects[15] - Development expenditures increased by 86.77% compared to the beginning of the year, primarily due to capitalized R&D expenditures from subsidiaries[15] - Other payables increased by 64.18% compared to the beginning of the year, mainly due to increased payables from the parent company and subsidiaries[15] - Accounts receivable decreased to CNY 740,175,538.77 from CNY 850,519,033.22, a decline of about 13.0%[22] - Cash and cash equivalents decreased to CNY 243,809,559.48 from CNY 508,073,915.35, a significant drop of approximately 52.0%[22] - Inventory increased to CNY 391,546,841.75 from CNY 376,324,551.24, showing a rise of about 4.0%[22] - Short-term borrowings remained unchanged at CNY 1,000,000.00[23] - The company reported a decrease in employee compensation payable from CNY 57,213,279.92 to CNY 39,814,873.65, a reduction of approximately 30.0%[23]

2018 年半年度报告 公司代码：600479 公司简称：千金药业 株洲千金药业股份有限公司 2018 年半年度报告 1 / 161 2018 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人江端预、主管会计工作负责人谢爱维及会计机构负责人（会计主管人员）谭素娥 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的未来计划等前瞻性陈述，不构成公司对投资者的实质承诺，请投资者 注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 重大风险提示 报告期内，不存在对公司生产经营产生实质性影响的特别重大风险。公司已在本报告 第四节经营情况的讨论与分析中"可能面对的风险"进行了提示，请查阅。 十、 其 ...

Financial Performance - In 2017, the company's operating revenue reached ¥3,182,743,792.32, an increase of 11.09% compared to ¥2,864,885,512.19 in 2016[20] - The net profit attributable to shareholders of the listed company for 2017 was ¥207,758,270.50, representing a growth of 39.04% from ¥149,428,673.21 in 2016[20] - The net profit after deducting non-recurring gains and losses was ¥173,100,327.49, which is an increase of 28.39% compared to ¥134,820,940.05 in the previous year[20] - Cash flow from operating activities amounted to ¥283,466,753.63, a significant increase of 101.2% from ¥140,879,318.95 in 2016[20] - As of the end of 2017, total assets were ¥3,286,881,188.90, an increase of 8.40% from ¥3,032,091,192.71 at the end of 2016[20] - The net assets attributable to shareholders of the listed company were ¥1,877,407,342.85, reflecting a growth of 7.55% from ¥1,745,666,243.54 in 2016[20] - Basic earnings per share increased by 39.02% to CNY 0.5957, driven by a significant rise in net profit attributable to shareholders[21] - Operating cash flow increased by 101.21%, attributed to higher cash receipts from sales and reduced cash payments related to operating activities[22] - The weighted average return on equity rose to 11.47%, an increase of 2.66 percentage points compared to the previous year[21] Dividends and Capital Management - The company proposed a cash dividend of ¥3 per 10 shares, based on a total share capital of 348,755,931 shares as of December 31, 2017[5] - The company plans to increase its capital reserve by converting 2 shares for every 10 shares held, based on the same total share capital[5] - The company has achieved a cumulative distributable profit of ¥694,236,327.51, including retained earnings from previous distributions[5] Market Position and Product Portfolio - The company has a total of 122 drug registration certificates and 215 patented technologies, indicating a strong product portfolio[33] - The company is expanding its business model to include a full pharmaceutical industry chain, covering manufacturing, distribution, and traditional Chinese medicine cultivation[34] - The company aims to extend its focus from gynecology to the broader female health sector, aligning with its strategic development goals[34] - The company has 41 drugs included in the National Basic Medical Insurance Drug List, enhancing its market presence[33] - The company’s brand "Qianjin" is recognized as a famous Chinese trademark, leading in the domestic gynecological medication market[33] - The brand value of "Qianjin" reached CNY 1.559 billion, ranking first in the gynecological medication category for three consecutive years[40] Industry Trends and Challenges - The pharmaceutical industry in China saw a 12.39% year-on-year increase in main business revenue, reaching CNY 15,314.40 billion in the first half of 2017[37] - The total profit of the pharmaceutical industry increased by 15.83% year-on-year, amounting to CNY 1,686.52 billion in the same period[37] - The pharmaceutical industry’s profit margin was 11.01%, exceeding the national industrial average by 3.88 percentage points[37] - The company faces risks related to raw material price fluctuations, drug quality, industry policies, and research and development[9] Research and Development - The R&D expenditure increased by 31.49% to approximately ¥84.02 million, reflecting the company's commitment to innovation[53] - The company employs 274 technical personnel, with 90% holding a bachelor's degree or higher, and has a strong team for new drug development and technological innovation[42] - The company has 201 patents, including 37 invention patents, and is currently developing 2 new drug projects and 5 secondary development projects[92] - The company is focusing on the consistency evaluation of generic drugs, with an estimated evaluation cost of nearly 10 million yuan per product, targeting drugs with stable raw material supply and good market prospects[102] Sales and Marketing Strategy - The company has established a marketing network covering over 2000 hospitals and 30,000 grassroots medical institutions, achieving a 95% distribution rate for gynecological products across three sales terminals[42] - The company’s marketing strategy focuses on county-level markets and has implemented a three-terminal marketing system to enhance operational efficiency[41] - The company’s sales model includes a commercial segment, OTC segment, and a medical segment, with a focus on maintaining price stability and reducing competition through a controlled sales approach[109] Environmental and Social Responsibility - The company has committed to enhancing its environmental management system and increasing investment in environmental protection measures[180] - The company actively participated in poverty alleviation efforts, ensuring that all 38 households and 137 individuals in the targeted village were lifted out of poverty[170] - The company invested a total of 20 million RMB in poverty alleviation projects, helping 30 registered impoverished individuals to escape poverty[173] Future Outlook and Strategic Initiatives - The company plans to enhance its infrastructure by improving roads, water conservancy, and communication systems in the targeted village[169] - The company aims to achieve "three unifications" in its group strategy, including unified leadership, mechanisms, and culture[136] - The company plans to enhance the development of wild medicinal materials and has established a dedicated company at the source to support farmers, aiming for sustainable supply[138] - The company is focusing on expanding its market presence through strategic acquisitions and partnerships in response to regulatory changes[84]

Financial Performance - Operating revenue rose by 4.98% to CNY 690,326,657.69 year-on-year[6] - Net profit attributable to shareholders increased by 22.37% to CNY 33,941,603.37 compared to the same period last year[6] - Basic earnings per share increased by 22.39% to CNY 0.0973[6] - The profit attributable to shareholders of the parent company was CNY 33,941,603.37, up 22.4% from CNY 27,737,539.41 in the previous year[35] - Basic and diluted earnings per share for Q1 2018 were CNY 0.0973, compared to CNY 0.0795 in Q1 2017, reflecting a growth of 22.5%[35] - Net profit for Q1 2018 reached CNY 42,422,124.99, representing a 23% increase compared to CNY 34,497,671.49 in Q1 2017[34] Cash Flow - Cash flow from operating activities decreased by 57.18% to CNY 20,607,771.58 compared to the previous year[6] - The net cash flow from operating activities decreased by 57.18% year-on-year, amounting to CNY 20,607,771.58, due to increased tax payments[20] - The company reported a cash flow from operating activities of CNY 19,110,516.20 for Q1 2018, compared to CNY 15,407,615.32 in Q1 2017, indicating a growth of 24%[37] - Net cash flow from operating activities decreased to ¥20,607,771.58 from ¥48,127,310.81, reflecting a decline of 57.1%[39] - Total cash outflow from operating activities was ¥1,046,030,103.62, up from ¥850,008,656.02, reflecting a rise of 23.1%[39] Assets and Liabilities - Total assets increased by 1.87% to CNY 3,348,250,885.89 compared to the end of the previous year[6] - Total current assets increased to CNY 2,487,548,833.50 from CNY 2,429,237,726.97, representing a growth of approximately 2.4%[25] - Total non-current assets amounted to CNY 860,702,052.39, slightly up from CNY 857,643,461.93, indicating a marginal increase of 0.1%[26] - Total liabilities rose to CNY 1,064,660,989.43 from CNY 1,045,713,417.43, an increase of approximately 1.4%[27] - Total equity increased to CNY 2,283,589,896.46 from CNY 2,241,167,771.47, representing a growth of about 1.9%[27] - The company’s total liabilities to equity ratio stands at approximately 46.6%[27] Shareholder Information - The total number of shareholders reached 26,673 at the end of the reporting period[9] - The largest shareholder, Zhuzhou State-owned Assets Investment Holding Group, holds 28.53% of the shares[9] Investment and Income - Investment income increased by 127.80% year-on-year, reaching CNY 410,560.59, driven by higher returns from matured financial products[19] - Other income doubled compared to the previous year, amounting to CNY 2,915,573.45, due to increased government subsidies[19] - The company reported a significant increase in fair value gains of 4527.59% year-on-year, reaching CNY 3,150,492.94[19] - Non-recurring gains and losses totaled CNY 5,558,526.46 after tax adjustments[10] Accounts Receivable and Inventory - Accounts receivable grew by 85.29% year-on-year, totaling CNY 287,788,211.53, attributed to expanded sales and collection policies[14] - Other receivables increased by 79.65% compared to the previous year, amounting to CNY 137,079,685.47, mainly due to increased petty cash[14] - Inventory increased to CNY 413,550,730.60 from CNY 376,324,551.24, reflecting a growth of about 9.9%[25] Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[34] - The company anticipates potential significant changes in cumulative net profit compared to the previous year, but no specific details were provided[23]

Financial Performance - Net profit attributable to shareholders rose by 41.57% to CNY 85,417,895.35 for the third quarter[7] - Operating revenue for the first nine months increased by 14.75% to CNY 2,280,331,808.96 compared to the same period last year[6] - Basic earnings per share increased by 48.20% to CNY 0.2798[7] - Net profit attributable to the parent company increased by 48.17% year-on-year, reaching approximately RMB 97.58 million[21] - Total revenue for the third quarter reached ¥767,718,555.14, an increase of 8.2% compared to ¥709,002,869.31 in the same period last year[37] - Net profit for the third quarter was ¥63,068,858.30, representing a 69.5% increase from ¥37,209,242.37 in the previous year[38] - The company's operating profit for the first nine months of 2017 was ¥88,606,218.47, compared to ¥48,724,654.60 for the same period in 2016, indicating a growth of approximately 81.9%[40] - The total profit for the first nine months of 2017 was ¥89,069,523.39, up from ¥49,742,773.48 in the previous year, which is an increase of approximately 79.4%[41] Assets and Liabilities - Total assets increased by 2.72% to CNY 3,114,615,215.54 compared to the end of the previous year[6] - Total liabilities as of September 30, 2017, were 996,347,613.94 yuan, compared to 948,212,145.28 yuan at the beginning of the year[32] - The company's total assets increased to ¥1,745,145,978.22 from ¥1,676,829,835.21, marking a growth of 4.1%[35] - Current assets totaled ¥1,270,380,038.77, up from ¥1,195,926,868.46, indicating a rise of 6.9%[34] - Total liabilities increased to ¥260,401,035.70 from ¥200,204,956.12, reflecting a rise of 30.0%[36] Cash Flow - Net cash flow from operating activities for the first nine months increased by 7.74% to CNY 177,753,186.38[6] - Net cash flow from operating activities increased by 12,763,111.10 yuan, a rise of 7.74% year-on-year, driven by increased sales revenue and the maturity of bank acceptance bills[27] - Net cash flow from investing activities decreased by 25,547,090 yuan, primarily due to an increase in net short-term investments[27] - Net cash flow from financing activities decreased by 1,319,560 yuan, mainly due to an increase in dividend distribution compared to the same period last year[27] - The cash inflow from operating activities for the period from January to September reached ¥2,835,409,379.29, an increase of 15.9% compared to ¥2,444,964,230.01 in the same period last year[43] - The net cash flow from operating activities in the third quarter was ¥159,875,352.41, significantly up from ¥4,209,956.83 year-over-year[47] Shareholder Information - The total number of shareholders reached 30,845 by the end of the reporting period[11] - The largest shareholder, Zhuzhou State-owned Assets Investment Holding Group, holds 26.58% of the shares[11] Government Subsidies and Other Income - The company received government subsidies amounting to CNY 8,880,010.28 during the first nine months[9] - Other income doubled compared to the same period last year, with government subsidy income increasing by 92.07% year-on-year due to the implementation of new accounting standards[23] Investment and Development - Development expenditures increased by 250.7% compared to the beginning of the year, primarily due to increased development spending by a subsidiary[19] - Long-term equity investments increased by 100% compared to the beginning of the year, attributed to investments in joint ventures by a subsidiary[18] - The company reported a significant increase in investment income to ¥2,348,339.59 from ¥1,036,340.64, an increase of 126.5%[38] - The company reported investment income of ¥19,372,522.70 for the first nine months of 2017, significantly higher than ¥8,218,431.50 in the same period of 2016, representing an increase of approximately 135.7%[40] Financial Metrics - The weighted average return on net assets increased by 1.51 percentage points to 5.47%[7] - Financial revenue increased by 50.62% compared to the same period last year, primarily due to the increase in interest income from bank wealth management products[23] - Asset impairment losses increased by 72.84% year-on-year, mainly due to the increase in accounts receivable and other receivables leading to higher bad debt provisions[23] - Fair value changes in income increased by 1054.21% year-on-year, primarily due to the appreciation of funds held during the period[23]

重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、 准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法 律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 2017 年半年度报告 公司代码：600479 公司简称：千金药业 株洲千金药业股份有限公司 2017 年半年度报告 四、 公司负责人江端预、主管会计工作负责人谢爱维 及会计机构负责人（会计主管 人员）谭素娥声明：保证半年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的未来计划等前瞻性陈述，不构成公司对投资者的实质承诺，请投资者 注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 1 / 158 2017 年半年度报告 九、 重大风险提示 报告期内，不存在对公司生产经营产生实质性影响的特别重大风险。公司已在本报告 第四节经营情况的讨论与分析中"可能面对的风险"进行了提示，请查阅。 十、 ...

Financial Performance - Net profit attributable to shareholders rose by 32.28% to CNY 27,737,539.41 year-on-year[6] - Operating revenue grew by 26.33% to CNY 657,602,206.76 compared to the same period last year[6] - Basic earnings per share increased by 32.28% to CNY 0.0795[6] - The net profit after deducting non-recurring gains and losses increased by 43.97% to CNY 26,628,794.92[6] - Net profit for Q1 2017 was ¥34,497,671.49, representing a 69.4% increase from ¥20,351,153.44 in Q1 2016[33] - Earnings per share for Q1 2017 were ¥0.0795, compared to ¥0.0601 in the previous year, reflecting a growth of 32.3%[33] Cash Flow - The net cash flow from operating activities was CNY 48,127,310.81, a significant recovery from a negative cash flow of CNY -2,066,431.88 in the previous year[6] - The net cash flow from operating activities increased by CNY 50.19 million compared to the same period last year, primarily due to an increase in sales revenue and the maturity of bank acceptance bills[21] - The net cash flow from investing activities decreased by CNY 621.91 million year-on-year, mainly due to an increase in net investment[21] - The net cash flow from financing activities increased by CNY 2.70 million compared to the same period last year, as the company did not need to repay loans this period, unlike the previous year[21] - The net cash flow from operating activities for Q1 2017 was ¥48,127,310.81, a significant improvement from a loss of ¥2,066,431.88 in the same period last year[37] - The total cash outflow from operating activities was ¥850,008,656.02, compared to ¥722,444,951.10 in the same period last year, representing an increase of about 17.7%[37] Assets and Liabilities - Total assets increased by 2.64% to CNY 3,112,261,553.29 compared to the end of the previous year[6] - Total current assets as of March 31, 2017, amounted to CNY 2,212.33 million, an increase from CNY 2,133.00 million at the beginning of the year[25] - Total assets as of March 31, 2017, were CNY 3,112.26 million, up from CNY 3,032.09 million at the beginning of the year[27] - Total liabilities increased to CNY 993.88 million from CNY 948.21 million, showing a rise of approximately 4.8%[27] - Total liabilities for Q1 2017 were ¥215,367,728.46, up from ¥200,204,956.12 in the same period last year, indicating an increase of 7.9%[30] Shareholder Information - The total number of shareholders reached 26,273 at the end of the reporting period[12] - The largest shareholder, Zhuzhou State-owned Assets Investment Holdings, holds 26.58% of the shares[12] Expenses - Sales expenses increased by 56.72% year-on-year, driven by higher sales in the high-cost pharmaceutical production and hygiene products sectors[18] - Management expenses increased by 37.51% year-on-year, largely due to a significant increase in R&D investment[19] - Operating tax and additional fees increased by 70.12% year-on-year, mainly due to increased operating income and changes in VAT accounting policies[17] Other Financial Metrics - The weighted average return on equity increased by 0.31 percentage points to 1.58%[6] - Non-recurring gains and losses totaled CNY 1,108,744.49 for the reporting period[9] - The company reported a significant increase in government subsidy income, leading to a 126.67% increase in non-operating income year-on-year[19] - The company reported a significant increase in other receivables, rising to CNY 119.07 million from CNY 57.03 million, which is an increase of approximately 108.9%[25] - The company recorded an investment income of ¥180,230.70 in Q1 2017, a decrease from ¥2,262,429.67 in the same period last year[33]